The Relationship Between Pan-immune-inflammation Value and Survival in Breast Cancer Patients

The aim of this study was to investigate the effect of pan-immune-inflammation value (PIV), one of the inflammation markers, on progression-free survival (PFS) and overall survival (OS) in patients diagnosed with breast cancer, and the factors affecting PFS and OS. The files of patients who received adjuvant treatment for breast cancer at the radiation oncology outpatient clinic of Kayseri Education and Research Hospital were retrospectively scanned. The relationship between PIV value and OS and PFS was investigated. Three hundred female patients who underwent modified radical mastectomy were included in the study. The average age was 55 years. Ninety-five percent of the patients received chemotherapy, 69.3% of the patients received radiotherapy, and 61.3% of the patients received hormonal therapy. The PIV cutoff value was determined as 278, and PIV was above 278 in 176 (58.6%) patients. When the chi-square test was performed for PIV values, it was seen that the menopause factor was effective. OS mean was 79.7 months and PFS mean was 79.2 months. Thirty-seven cases died due to disease or non-disease reasons. Local recurrence and/or distant metastasis was detected in 40 cases. Statistical significance was found between menopause status (p = 0.021). The factors that had a statistically significant effect in univariate and multivariate analysis were neutrophils (p = 0.004; OR, 1.1; CI, 1.0-1.2) and PIV value (p = 0.001; OR, 0.2; CI, 0.0-0.6). Those affecting PFS are neutrophil count (p = 0.018; OR, 1.1; CI, 1.0-1.2), PIV (p = 0.006; OR, 0.3; CI, 0.1-0.7), and monocyte PIV value (p = 0.025; OR, 01.8; CI, 1.0-3.1). High PIV value was found to be a poor prognostic factor in overall survival and disease-free survival in breast cancer patients who underwent modified radical mastectomy.